This fact sheet includes the latest information and data about the Medicare Part D prescription drug benefit, including current plan information, the standard benefit parameters, low-income assistance, the latest available enrollment data, and Part D program spending and financing.
This data note from the latest KFF Health Tracking Poll explores the public’s views on Medicare drug price negotiation, including how arguments on both sides impact support and opposition; confidence in leaders to do the right thing on drug pricing; and experiences with prescription drug costs.
Most of the Public Lacks Confidence that President Biden, Congressional Democrats or Republicans Will Do the Right Thing on Drug Prices Allowing the federal government to negotiate with drug companies to lower drug prices for Medicare beneficiaries and people enrolled in private plans – a key cost-saving proposal in the Democrats’ massive reconciliation bill –…More
As Congress debates cutting prescription drug costs, a poll released Tuesday found the vast majority of adults — regardless of their political party or age — support letting the federal government negotiate drug prices for Medicare beneficiaries and those in private health insurance plans. The argument that pharmaceutical companies need to charge high prices to …
The Public Backs Medicare Rx Price Negotiation Even After Hearing Both Sides’ Views Read More »
This policy watch evaluates the pharmaceutical industry’s claims that allowing the federal government to negotiate drug prices would restrict access to medications in Medicare. It explains what the current proposal to allow drug price negotiation would and wouldn’t do.
As President Joe Biden’s government overhaul stalls in Congress, tensions are mounting over what changes ― if any ― could come for Americans at the pharmacy counter. The proposals in flux range from tinkering with tax credits to far-reaching changes in federal payments systems. Pressure is building to contain costs that have skyrocketed over the …
What the Stalemate on Capitol Hill Means for Your Drug Prices Read More »
KHN correspondent Rachana Pradhan discussed why President Joe Biden hasn’t yet nominated a permanent leader for the Food and Drug Administration on Newsy’s “Morning Rush” on Thursday. Click here to hear Pradhan on “Morning Rush“ Read Pradhan’s “Public Health Experts ‘Flabbergasted’ That Biden Still Hasn’t Picked an FDA Chief” KHN freelancer Nick Ehli discussed Montana’s …
From the FDA’s Empty Seat to Chock-Full ICUs, Journalists Recap the Week’s Stories Read More »
Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. Democrats in Congress and the White House are feverishly negotiating to pass as much of President Joe Biden’s domestic agenda as they can agree on, even as …
KHN’s ‘What the Health?’: The Autumn of Democrats’ Discontent Read More »
It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal pain, digestion problems, fatigue, and hot, red rashes. And after learning in 2016 that she had Crohn’s disease, a chronic inflammation of the digestive tract, she spent more than four years trying medications before getting her disease under control with …
Biosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch? Read More »
Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. Congressional Democrats are finding it harder to actually write legislation to lower drug prices than it is to make promises about it. But the drug price provisions of the $3.5 trillion social-spending bill …
KHN’s ‘What the Health?’: Much Ado About Drug Prices Read More »
Medicare Part D, the outpatient prescription drug benefit for Medicare beneficiaries, provides coverage above a catastrophic threshold for high out-of-pocket drug costs, but there is no cap on total out-of-pocket drug costs that beneficiaries pay each year. Recent legislative proposals would add a cap on out-of-pocket spending under Part D. This analysis focuses on the …
Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. As covid-19 cases in the U.S. continue to rise, the Biden administration is countering with new strategies. The latest efforts include preparing for vaccine boosters starting this …
Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. The Senate has set the stage for a busy fall that will include debate on a broad array of health issues, such as prescription drug prices, Medicare …
Proposals to allow the federal government to negotiate prescription drug prices, such as H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, aim to lower out-of-pocket drug costs for Medicare beneficiaries and private plan enrollees and achieve savings for Medicare. This data note estimates average premium savings attributable to the negotiations provision of …
How Would Drug Price Negotiation Affect Medicare Part D Premiums? Read More »
To several U.S. senators, it looked wasteful, even outrageous. Every year, taxpayers pay for at least $750 million worth of expensive pharmaceuticals that are simply thrown away. Companies ship many of the drugs in “Costco”-size vials, one lawmaker said, that once opened usually cannot be resealed or saved for other patients. Yet pharma gets paid …
The Senate’s release of its bipartisan infrastructure plan signals that lawmakers are poised to throw former President Donald Trump’s belated bid to lower Medicare drug prices under the bus — not to mention trains, bridges, tunnels and broadband connections. That’s because the massive spending bill is the first of two likely to at least delay …
2+2=? Senate Uses Murky Math as It Shelves Drug Pricing Rule to Fund Infrastructure Read More »
The long list of side effects that follow ads for the newer expensive drugs to treat Type 2 diabetes sometimes include an unusual warning: They might cause weight loss. That side effect is one that many people — especially those with Type 2 diabetes, which is associated with obesity — may desperately want. So it’s …
Diabetes Drug’s New Weight Loss Formula Fuels Cost-Benefit Debate Read More »
These FAQs discuss recent efforts related to prescription drug importation, the history of this approach, challenges that previous efforts to carry out importation proposals have faced, and stakeholder views.
Kathi Arbini said she felt elated when Missouri finally caught up to the other 49 states and approved a statewide prescription drug monitoring program this June in an attempt to curb opioid addiction. The hairstylist turned activist estimated she made 75 two-hour trips in the past decade from her home in Fenton, a St. Louis …
As Holdout Missouri Joins Nation in Monitoring Opioid Prescriptions, Experts Worry Read More »
KHN Midwest correspondent Lauren Weber discussed outbreaks caused by the covid-19 delta variant in Missouri and elsewhere on Newsy on Thursday. Click here to watch Weber on Newsy Read Weber’s “The Delta Variant Thrives in a State of Political and Public Health Discord“ KHN correspondent Aneri Pattani discussed opioids and the rise in overdose deaths …
Journalists Dig in on Delta Variant Risks and Opioid Overdose Deaths Read More »
Nearly 3 million Medicare Part D enrollees had out-of-pocket drug spending above the catastrophic threshold in a recent five-year period, finds a new KFF analysis that takes a comprehensive look at how many people on Medicare have drug expenses high enough to push them above that limit. While the Part D drug benefit has helped…More
In response to prescription drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing the federal government to negotiate the price of prescription drugs for Medicare and private payers. This brief describes the current status of drug price negotiation proposals, looks back at the history of proposals to give the federal …
What’s the Latest on Medicare Drug Price Negotiations? Read More »
Medicare Part D, the outpatient prescription drug benefit for Medicare beneficiaries, provides catastrophic coverage for high out-of-pocket drug costs, but there is no limit on the total amount that beneficiaries have to pay out of pocket each year. Policymakers on both sides of the aisle support proposals to modify the design of the Part D …
Do you sometimes lose your train of thought or feel a bit more anxious than is typical for you? Those are two of the six questions in a quiz on a website co-sponsored by the makers of Aduhelm, a controversial new Alzheimer’s drug. But even when all responses to the frequency of those experiences are …
Facing Headwinds on New Alzheimer’s Drug, Biogen Launches Controversial Campaign Read More »
Exactly what American health care will look like if Democrats can pass their $3.5 trillion spending plan is unclear, but the senator negotiating its health-related provisions hopes what emerges will be dramatic: the first complete health care system for older Americans and significantly reduced costs for everyone else. “We are setting very, very ambitious goals,” …
Sen. Wyden: $3.5T Budget May Have to Trim but It Can Set a Path to ‘Ambitious Goals’ Read More »
President Joe Biden’s executive order of July 9 included various steps toward making good on campaign promises to take on pharmaceutical companies by allowing the importation of prescription drugs and curbing the high cost of medicines. These issues were key to candidate Biden’s 2020 health care platform, which stated he would “stand up to abuse …
Biden’s July Executive Order Includes Drug Pricing Provisions. But Will They Do Enough? Read More »
KHN senior Colorado correspondent Markian Hawryluk discussed how a rural Colorado town is crowdsourcing ways to get prescription medicines delivered on KUNC’s “Colorado Edition” on Monday. Click here to hear Hawryluk on KUNC Read Hawryluk’s “How One Rural Town Without a Pharmacy Is Crowdsourcing to Get Meds“ KHN Editor-in-Chief Elisabeth Rosenthal discussed how medical education …
Journalists’ Topics Range From Rural Pharmacy Deserts to Opioid Overdoses Read More »
Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. The expansion of health benefits is a major piece of the tentative budget deal reached this week by Democrats in Congress. They plan to press ahead — …
KHN’s ‘What the Health?’: Here Comes Reconciliation Read More »
The budget package Democrats are assembling in Congress would likely provide the biggest jolt to the American health care system since the passage of the Affordable Care Act in 2010, according to sources familiar with work on the plan. Democrats in the Senate announced Tuesday night that they had reached a framework for a $3.5 …
Senate Democrats’ Plan Boosts Spending on Medicare, ACA Subsidies, Long-Term Care Read More »
The Biden administration will support whatever expansions to Medicare Congress is willing to make, Health and Human Services Secretary Xavier Becerra said Tuesday. Democratic lawmakers on Capitol Hill are working on plans both to add benefits to the health program for seniors and to lower its eligibility age from 65 to 60. But the efforts …
As Congress Wrestles With Plans to Expand Medicare, Becerra Says Any One Will Do Read More »
The brief examines the potential impact of Aduhelm, a newly approved drug for Alzheimer’s disease, on state and federal Medicaid costs and looks at potential policy actions that could limit Medicaid’s potential costs.
If you could invest $56 billion each year in improving health care for older adults, how would you spend it? On a hugely expensive medication with questionable efficacy — or something else? This isn’t an abstract question. Aduhelm, a new Alzheimer’s drug approved by the Food and Drug Administration last month, could be prescribed to …
Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead? Read More »
WALDEN, Colo. — The building that once housed the last drugstore in this town of fewer than 600 is now a barbecue restaurant, where pit boss Larry Holtman dishes out smoked brisket and pulled pork across the same counter where pharmacists dispensed vital medications more than 30 years ago. It’s an hourlong drive over treacherous …
How One Rural Town Without a Pharmacy Is Crowdsourcing to Get Meds Read More »
Under pressure to rein in skyrocketing prescription drug costs, states are targeting companies that serve as conduits for drug manufacturers, health insurers and pharmacies. More than 100 separate bills regulating those companies, known as pharmacy benefit managers, have been introduced in 42 states this year, according to the National Academy for State Health Policy, which …
States Step Up Push to Regulate Pharmacy Drug Brokers Read More »
This charticle draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.
The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S. This brief analyzes the cost implications for Medicare and beneficiaries associated with Biogen’s new FDA-approved Alzheimer’s drug, which will …
Prescription drug spending in Medicaid and other health programs has returned to the national policy debate. This analysis examines Medicaid outpatient prescription drug utilization and spending before rebates over the 2015 to 2019 period, which is helpful for understanding recent cost drivers and areas for targeted policy action.
The Medicare Part D program provides an outpatient prescription drug benefit to older adults and people with long-term disabilities in Medicare who enroll in private plans, including stand-alone drug plans and Medicare Advantage drug plans. This analysis provides the latest data about Part D enrollment, premiums, and cost sharing in 2021 and trends over time.
With increased attention to the global need for COVID-19 vaccines and the Biden administration’s announcement today about how it plans to distribute the first portion of the 80 million doses it will share by the end of this month, the latest KFF Health Tracking Poll finds that two-thirds of the public (66%) say that the…More
The latest KFF Health Tracking Poll explores the public’s views on the U.S. role in distributing COVID vaccines to other countries, health care priorities for Congress, prescription drug regulations and price negotiations, and affordability changes in the COVID-19 relief bill.
California Healthline editor Arthur Allen discussed the investigation into the origins of the coronavirus on KPBS’ “Midday Edition” on Wednesday. Click here to hear Allen on KPBS Read Allen’s “To the Bat Cave: In Search of Covid’s Origins, Scientists Reignite Polarizing Debate on Wuhan ‘Lab Leak’“ Senior Colorado correspondent Markian Hawryluk discussed Colorado’s efforts to …
KHN Journalist Combs for Clues on Covid’s Origins Read More »
Use Our Content It can be republished for free. The Biden administration said Friday it has no timeline on whether it will allow states to import drugs from Canada, an effort that was approved under President Donald Trump as a key strategy to control costs. Six states have passed laws to start such programs, and Florida, Colorado and New Mexico are the furthest along in plans to get federal approval. The …
Biden Administration Signals It’s in No Rush to Allow Canadian Drug Imports Read More »
Nykerrius Williams knows about the close relationship between hip-hop and opioid use. Williams, 27, an independent rapper from Gibsland, Louisiana, who goes by the name Young Nyke, took oxycodone pills for the first time when he was 16 and has continued patterns of misuse of those pills, as well as Lortabs, Xanax and codeine cough …
Opioids like ‘Lean’ Permeate Hip-Hop Culture, but Dangers Are Downplayed Read More »
DENVER — Tired of waiting for federal action to reduce prescription drug costs, Colorado is acting on its own — even if it must do so with one arm tied behind its back. Unable to set prices or change patent protections, the state is exploring creative legislative and administrative approaches to lower out-of-pocket costs on …
Colorado Lawmakers Wage Multifront Assault on High Drug Costs Read More »
Although attention in current federal actions is largely focused on Medicare and private insurance drug prices, federal legislation also has been recently introduced or enacted that would affect Medicaid prescription drug policy.
Even prior to the COVID-19 pandemic, hormonal contraception became more accessible to many outside of traditional clinical settings through websites or apps that offer contraception via telehealth. To better understand this emerging method of contraceptive access, a new KFF analysis provides a deeper look at telecontraception platforms, offering insights into the practices of 13 different…More
Can’t see the audio player? Click here to listen on SoundCloud. The high cost of prescription drugs is a top health issue for the public and politicians, but concerns raised by a group of moderate Democrats threaten to derail a bill being pushed by House Democratic leaders. Meanwhile, the Food and Drug Administration has authorized the …
KHN’s ‘What the Health?’: Drug Price Effort Hits a Snag Read More »
This brief examines how leading federal and state policy options related to changes in Medicaid Drug Rebate Program (MDRP), drug pricing, and payment and management of the Medicaid prescription drug would affect state and federal governments as well as private industry (including drug manufacturers, managed care organizations, and pharmacies).
One of the few surprises in President Joe Biden’s social safety-net proposal, the American Families Plan, was something that didn’t make it into the final version: any mention of reining in the price of prescription drugs. Use Our Content It can be republished for free. The American Families Plan, the second part of Biden’s expansive …
Democrats Disagree About How to Spend Potential Prescription Drug Windfall Read More »
Can’t see the audio player? Click here to listen on SoundCloud. It’s been a busy 100 days for the Biden administration on health policy. The promise Joe Biden made as president-elect to get 100 million covid vaccinations in arms was doubled, healthcare.gov reopened to those without insurance, and steps were taken to undo a raft of …
KHN’s ‘What the Health?’: 100 Days of Health Policy Read More »
Covid survivors are at risk from a possible second pandemic, this time of opioid addiction, given the high rate of painkillers being prescribed to these patients, health experts say. Use Our Content It can be republished for free. A new study in Nature found alarmingly high rates of opioid use among covid survivors with lingering …
A new KFF analysis finds that a relatively small share of drugs, mainly those without generic or biosimilar competitors, accounted for a disproportionate share of prescription drug spending in Medicare in 2019. This finding suggests that recent proposals that focus on prices for a limited number of high-cost drugs could achieve significant savings. The 250…More
As policymakers focus attention on proposals to lower prescription drug costs by allowing price negotiation or international reference pricing for a limited number of drugs, this analysis measures the share of total Medicare Part D and Part B prescription drug spending accounted for by top-selling drugs covered under each part.
Chuck Peterson of Omaha, Nebraska, recently experienced a swollen, painful knuckle caused by arthritis. He got a prescription for colchicine. Doctors have used the drug for treating gout and other rheumatic conditions for well over two centuries. When Peterson went to the pharmacy, he was shocked to discover that a two-month supply of 120 pills, …
The FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar Read More »
Can’t see the audio player? Click here to listen on SoundCloud. Congress is out of session, but that hasn’t stopped Democrats from planning their next round of health legislation. Together with President Joe Biden, they are looking at a broad array of possibilities, from allowing Medicare to negotiate drug prices to adding more benefits to the …
KHN’s ‘What the Health?’: Planning for Round Two Read More »
¿Podría un antidepresivo que se usa desde hace décadas ser un arma secreta contra covid? Algunos científicos creen que sí, después de que dos pequeños estudios demostraran que la fluvoxamina, que se suele recetar para el trastorno obsesivo compulsivo (TOC), evitara que los participantes desarrollaran una forma grave de la enfermedad. Sería algo impresionante. Un …
Medicamentos ya conocidos, y baratos, podrían ser clave para tratar covid Read More »
Could a decades-old antidepressant be a secret weapon against covid? A few scientists think so, after two small studies showed that fluvoxamine, typically prescribed for obsessive-compulsive disorder, prevented serious illness in all participants who took the pills soon after developing symptoms. This story also ran on San Francisco Chronicle. It can be republished for free. …
Scientists Seek Covid Treatment Answers in Cheap, Older Drugs Read More »
KHN has put together an interactive tool of significant health policies implemented by the Trump administration using its own authority — executive orders, agency guidance or formal regulations — and is tracking Biden administration and court actions. We will update this chart as actions are taken. Topics: Affordable Care Act | HHS Operations | Immigration …
The Great Undoing: Which of Trump’s Policies Will Biden Reverse? Read More »
Can’t see the audio player? Click here to listen on SoundCloud. As questions swirl about the covid vaccine made by AstraZeneca, public health experts are worried the confusion could create more doubts among people already hesitant to get a vaccine. Meanwhile, the first Senate-confirmed officials are settling into their offices at the Department of Health and …
KHN’s ‘What the Health?’: Getting Down to Work at HHS Read More »
This brief examines how the CMS Innovation Center (also known as CMMI) and Section 402 demonstration authority could become pathways for the Biden Administration to implement policy changes related to prescription drug costs.
Democrats, newly in control of Congress and the White House, are united behind an idea that Republican lawmakers and major drugmakers fiercely oppose: empowering the Department of Health and Human Services to negotiate the prices of brand-name drugs covered by Medicare. This story also ran on Fortune. It can be republished for free. But they …
Democrats Eye Medicare Negotiations to Lower Drug Prices Read More »
This brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that were voted on but not enacted in …
As context for understanding the rationale for efforts to limit drug price increases, this analysis compares changes in list prices for drugs covered by Medicare Part D in 2019 to the inflation rate, based on data from the most recent Medicare Part D drug spending dashboard from the Centers for Medicare & Medicaid Services (CMS).
With the inauguration of President Biden and Democrats holding a slim majority in Congress, policymakers are likely to consider whether and how to reverse various health policy regulations issued by the Trump Administration.
ST. LOUIS — The public service announcement showed a mother finding her teenage son lifeless, juxtaposed with the sound of a ukulele and a woman singing, “That’s how, how you OD’d on heroin.” It aired locally during the 2015 Super Bowl but attracted national attention and has been viewed more than 500,000 times on YouTube. …
Are Public Health Ads Worth the Price? Not if They’re All About Fear Read More »
The party split in Congress is so slim that, even with Democrats technically in the majority, passing major health care legislation will be extremely difficult. So speculation about President-elect Joe Biden’s health agenda has focused on the things he can accomplish using executive authority. Although there is a long list of things he could do, …
Biden’s First Order of Business May Be to Undo Trump’s Policies, but It Won’t Be Easy Read More »
In this column for the JAMA Health Forum, Larry Levitt explores what President-elect Biden might do to advance his health care vision both through legislation and through executive orders and waivers and demonstrations.
Ted Howard started taking Truvada a few years ago because he wanted to protect himself against HIV, the virus that causes AIDS. But the daily pill was so pricey he was seriously thinking about giving it up. Under his insurance plan, the former flight attendant and customer service instructor owed $500 in copayments every month …
Many Health Plans Now Must Cover Full Cost of Expensive HIV Prevention Drugs Read More »
This story also ran on Fortune. It can be republished for free. Sharon Clark is able to get her life-sustaining cancer drug, Pomalyst — priced at more than $18,000 for a 28-day supply — only because of the generosity of patient assistance foundations. Clark, 57, a former insurance agent who lives in Bixby, Oklahoma, had …
Seniors Face Crushing Drug Costs as Congress Stalls on Capping Medicare Out-Of-Pockets Read More »
As the U.S. prepares for nationwide distribution of vaccines to combat COVID-19, some are asking whether people who get the first of two doses will return to complete the series in order to be fully immunized. This analysis draws on Medicare Part D prescription drug claims data for the herpes zoster vaccine Shingrix, which also …
Who Didn’t Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines Read More »
This brief outlines the potential health policy actions that President Biden could take using executive authority, based on campaign pledges, and actions that would reverse or modify regulations or guidance issued by the Trump Administration.
People buying their own health insurance have even more to think about this year, particularly those post-COVID-19 patients with lingering health concerns, the “long haulers,” who join the club of Americans with preexisting conditions. What type of plan is best for someone with an unpredictable, ongoing medical concern? That question is popping up on online …
During ACA Open Enrollment, Picking a Plan Invites New COVID Complications Read More »
The post Pregnant women warned to avoid some pain-relief drugs appeared first on Healthy Debate.
Health insurance companies will have to give their customers estimated out-of-pocket costs for prescription drugs and disclose to the public the negotiated prices they pay for drugs, under an unexpected new Trump administration rule. The administration said those requirements, part of a broader rule issued Oct. 29 forcing health plans to disclose costs and payments …
This issue brief provides an overview of the Medicare Part D prescription drug benefit plan landscape for 2021, with a focus on stand-alone drug plans. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D drug plans …
Medicare Part D: A First Look at Medicare Prescription Drug Plans in 2021 Read More »
The repeal of the ACA could mean loss of Medicaid coverage for up to 15 million that were enrolled in the ACA Medicaid expansion group prior to the COVID-19 pandemic; however, repeal could also mean significant changes to Medicaid prescription drug policy with implications for state and federal spending for prescription drugs for non-expansion Medicaid …
What Happens to Medicaid Drug Policy if the ACA is Overturned? Read More »
In an Axios column, Drew Altman discusses how this election year health isn’t a single issue — but several — and Joe Biden has the edge over President Trump on all of them, even as opposition to the ACA remains popular with Trump’s base.
During the first presidential debate of 2020, President Donald Trump touted his efforts to curb skyrocketing drug prices and declared that insulin is now “so cheap, it’s like water.” The response on social media was swift, and divided, with some people sharing pharmacy bills showing thousands of dollars they’d spent on insulin, while …
Progressive Group Highlights Trump, Tillis Weakness on Insulin Price Tags Read More »
This annual survey of employers provides a detailed look at trends in employer-sponsored health coverage, including premiums, employee contributions, cost-sharing provisions, offer rates, wellness programs, and employer practices. Annual premiums for employer-sponsored family health coverage reached $21,342 this year, up 4% from last year, with workers on average paying $5,588 toward the cost of their …
This slideshow explains the similarities and differences among major proposals to lower prescription drug costs introduced by the Trump Administration, members of Congress, and the Biden campaign.
This side-by-side comparison examines President Trump’s record and former Vice President Biden’s positions across a wide range of key health issues, including the response to the pandemic, the Affordable Care Act marketplace, Medicaid, Medicare, drug prices, reproductive health, mental health and opioids, immigration and health coverage, and health care costs.
DENVER — D.j. Mattern had her Type 1 diabetes under control until COVID’s economic upheaval cost her husband his hotel maintenance job and their health coverage. The 42-year-old Denver woman suddenly faced insulin’s exorbitant list price — anywhere from $125 to $450 per vial — just as their household income shrank. She scrounged extra insulin …
Not Pandemic-Proof: Insulin Copay Caps Fall Short, Fueling Underground Exchanges Read More »
This policy watch examines the likely impact of an executive order signed by President Trump in July 2020 related to prescription drugs, which would use lower international drug prices to set prices for a limited set of drugs in the U.S.
President Donald Trump has long considered lowering the high cost of prescription drugs to be one of his signature issues, and it is likely to be a talking point he relies on throughout the upcoming campaign. During his afternoon speech Monday ― delivered on the first day of the Repubublican National Convention after delegates had …
Trump Again Claims He’s Bringing Down Drug Prices, But Details of How Are Skimpy Read More »
Can’t see the audio player? Click here to listen on SoundCloud. Democrats have shown a remarkably united front, including on health care, in their socially distant, made-for-TV convention this week. That’s likely due, at least in part, to the physical separation of party members who disagree on issues — this year they cannot chatter on live …
KHN’s ‘What The Health?’: Democrats in Array (For Now) Read More »
Can’t see the audio player? Click here to listen on SoundCloud. California Sen. Kamala Harris, the newly named running mate for presumptive Democratic presidential nominee Joe Biden, doesn’t have a lot of background in health policy. But that’s unlikely to prevent Republicans from using her on-again, off-again support for “Medicare for All” against her in the …
KHN’s ‘What the Health?’: Kamala Harris on Health Read More »
These state fact sheets offer a snapshot of the administration and delivery of Medicaid pharmacy benefits in each state.
Can’t see the audio player? Click here to listen on SoundCloud. President Donald Trump’s pivot to a more serious view of the coronavirus pandemic didn’t last long. This week, he was again touting hydroxychloroquine, an antimalarial drug that has not been shown to work against the virus. Meanwhile, on Capitol Hill, Republicans continue to struggle to …
KHN’s ‘What The Health?’: Republicans in COVID Disarray Read More »
English
Afrikaans
Shqip
አማርኛ
العربية
Հայերեն
Azərbaycan dili
Euskara
Беларуская мова
বাংলা
Bosanski
Български
Català
Cebuano
Chichewa
简体中文
繁體中文
Corsu
Hrvatski
Čeština
Dansk
Nederlands
Esperanto
Eesti
Filipino
Suomi
Français
Frysk
Galego
ქართული
Deutsch
Ελληνικά
ગુજરાતી
Kreyol ayisyen
Harshen Hausa
Ōlelo Hawaiʻi
עִבְרִית
हिन्दी
Hmong
Magyar
Íslenska
Igbo
Bahasa Indonesia
Gaelige
Italiano
日本語
Basa Jawa
ಕನ್ನಡ
Қазақ тілі
ភាសាខ្មែរ
한국어
كوردی
Кыргызча
ພາສາລາວ
Latin
Latviešu valoda
Lietuvių kalba
Lëtzebuergesch
Македонски јазик
Malagasy
Bahasa Melayu
മലയാളം
Maltese
Te Reo Māori
मराठी
Монгол
ဗမာစာ
नेपाली
Norsk bokmål
پښتو
فارسی
Polski
Português
ਪੰਜਾਬੀ
Română
Русский
Samoan
Gàidhlig
Српски језик
Sesotho
Shona
سنڌي
සිංහල
Slovenčina
Slovenščina
Afsoomaali
Español
Basa Sunda
Kiswahili
Svenska
Тоҷикӣ
தமிழ்
తెలుగు
ไทย
Türkçe
Українська
اردو
O‘zbekcha
Tiếng Việt
Cymraeg
isiXhosa
יידיש
Yorùbá
Zulu